✦ LIBER ✦

Trial in progress: A randomized double-blind phase 3 trial comparing vintafolide+pegylated liposomal doxorubicin (PLD) versus PLD+placebo in patients with platinum-resistant ovarian cancer (PROCEED)

✍ Scribed by Naumann, R.W.; Gilbert, L.; Habbe, A.; Ma, H.; Ghamande, S.; Vergote, I.B.

Book ID: 127002188
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 58 KB
Volume: 133
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2014.03.466

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase III Trial of Gemcitabin

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer

✍ Mutch, D. G.; Orlando, M.; Goss, T.; Teneriello, M. G.; Gordon, A. N.; McMeekin, 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 325 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Ipilimumab versus placebo after radiothe

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

✍ Kwon, Eugene D; Drake, Charles G; Scher, Howard I; Fizazi, Karim; Bossi, Alberto 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 469 KB

Efficacy in Patient Subgroups in OCEANS,

Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)

✍ C. Aghajanian; S.V. Blank; B. Goff; P.L. Judson; S. Makhija; S.K. Sharma; L.R. N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

5002 ORAL Results from a Phase II random

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

✍ Makhija, S.; Glenn, D.; Ueland, F.; Dizon, D.; Paton, V.; Lin, C.Y.; Amler, L.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB